Skip Nav Destination
Issues
1 November 2009
-
Cover Image
Cover Image
The cover figure depicts proposed mechanisms of action of the promising natural preventive agent deguelin. Previous work has demonstrated that deguelin inhibits the phosphatidylinositol 3-kinase (PI3K)/AKT and nuclear factor kappa B (NF-κB) signaling pathways in regulating gene expression (left side). Now, novel findings reported in this issue of the journal demonstrate that deguelin also regulates the wnt/β-catenin pathway (right side) in ER-negative breast cancer cells. Deguelin inhibited both ER-positive and -negative breast-cancer cell growth, but most strongly in ER-negative cells, causing a cell-cycle blockade and inducing apoptosis. Deguelin joins only a small group of agents shown to inhibit the growth of ER-negative breast cancer cell lines. See articles by Murillo et al. (beginning on page 942) and Rodenberg and Brown (beginning on page 915) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Perspectives
Review
Research Articles
Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions
Anne S. Tsao; Diane Liu; Jack Martin; Xi-ming Tang; J. Jack Lee; Adel K. El-Naggar; Ignacio Wistuba; Kirk S. Culotta; Li Mao; Ann Gillenwater; Yuko M. Sagesaka; Waun K. Hong; Vassiliki Papadimitrakopoulou
Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients
Vikram D. Kekatpure; Jay O. Boyle; Xi Kathy Zhou; Anna J. Duffield-Lillico; Neil D. Gross; Nancy Y. Lee; Kotha Subbaramaiah; Jason D. Morrow; Ginger Milne; Scott M. Lippman; Andrew J. Dannenberg
Autofluorescence-Guided Surveillance for Oral Cancer
Vijayvel Jayaprakash; Maureen Sullivan; Mihai Merzianu; Nestor R. Rigual; Thom R. Loree; Saurin R. Popat; Kirsten B. Moysich; Soumya Ramananda; Timothy Johnson; James R. Marshall; Alan D. Hutson; Thomas S. Mang; Brian C. Wilson; Steven R. Gill; Jennifer Frustino; Arjen Bogaards; Mary E. Reid
Meeting Report
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.